Advisors

Scientific Advisory Board

Donald Kufe

Donald W. Kufe, M.D.

Harvard Medical School, Dana Farber Cancer Institute

Dr. Kufe is Professor of Medicine at Harvard Medical School, Distinguished Physician at the Dana-Farber Cancer Institute and co-Leader of the Developmental Therapeutics Program, Dana-Farber/Harvard Cancer Center.

 After a clinical fellowship in medical oncology at Dana-Farber Cancer Institute, he joined the staff in 1979. He has served as chief of the Division of Cancer Pharmacology, deputy director of the Dana-Farber/Harvard Cancer Center, director of the Harvard Phase I Oncology Group and leader of the Experimental Therapeutics Program. His career has focused on the development of new anti-cancer cytotoxic, targeted and immunotherapeutic agents, including vaccines.

Dr. Kufe has published over 600 papers and is an editor of the textbook “Cancer Medicine”. He is the recipient of the American Cancer Society Faculty Research Award, Burroughs Wellcome Scholar Award, Lung Cancer Research Foundation Scientific Merit Award and the Leukemia Lymphoma Society O’Dell Memorial Award. 

Dr. Kufe has founded companies that include Genus Oncology, GenVec (acquired by Intrexon), Convergence Pharmaceuticals (acquired by ILEX Oncology and Genzyme), Linus Oncology (acquired by Gibson Oncology) and NanoProteagen (merged with Hillstream).  

Paul Richardson

Paul Richardson, M.D

Director of Clinical Research, Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute

As Clinical Director of the Myeloma Center beginning in January 2001, Dr. Richardson leads novel, biologically-derived translational efforts in multiple myeloma under the overall direction and mentorship of Kenneth Anderson, M.D.

Currently, he leads efforts studying the use of combination therapies predominantly in relapsed and refractory myeloma, his primary area of interest. He serves as a principal investigator and study chairman for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity. His major leadership efforts are focused on the IFM/DFCI upfront study in patients eligible for stem cell transplant in combination with RVD. Finally, an important new area of interest for me is treatment-emergent neuropathy in myeloma, its characterization and strategies to minimize it.

Kwok-Kin Wong, M.D., Ph.D.

Director of Medical Hematology/Oncology, New York University


Joseph Paul Eder, M.D.

Professor of Medicine, Yale Cancer Center, Developmental Therapeutics Phase 1 Program

Dr. Eder is the Clinical Director of the Early Drug Development Program, performing Phase I clinical trials of new cancer medicines at Yale Cancer Center.

Previously he was the principal clinical investigator of the Harvard UO1 Phase I program, uniting the clinical efforts at the DFCI, BWH, MGH and BIDMC. He became the Clinical Director of the Experimental Therapeutics Program for the Dana-Farber/Harvard Cancer Center and as Clinical Director, assumed overall responsibility for the trials performed at the Dana Farber/HCC. He assumed the responsibilities as the Clinical Director of the DFCI General Cancer Research Center at the Dana-Farber/ Brigham and Women’s Hospital. These clinical and basic research activities have involved collaboration with clinical and basic scientists at Harvard and elsewhere, the Cancer Therapy Evaluation Program of the National Cancer Institute, presentations at national and international meetings, and correspondence with a number of leaders in the field of cancer drug development. 

While at AstraZeneca PLC, he was the Medical Science Director for AstraZeneca’s Boston site, responsible for the medical and clinical aspects of development of agents from chemical lead identification through clinical proof of concept in phase II, responsible for the design and interpretation of the entire clinical development plan for five agents. His position had global responsibilities with clinical trials in the US, Canada, European Union, Japan and Korea. He was a member of the Strategic Planning & Business Development as an ad hoc member and was the global Disease Area Clinical Expert for Hematology.

Dr Eder obtained his medical degree at Georgetown University School of Medicine and was a fellow at Dana Farber Cancer Institute completing fellowships at Beth Israel Hospital and Georgetown University Hospital.

Ralph Weichselbaum, M.D.

D.K. Ludwig Professor and Chairman at the University of Chicago Medical Center

Ralph R. Weichselbaum, M.D., is Daniel K. Ludwig Distinguished Service Professor of Radiation Oncology and Chairman, Department of Radiation and Cellular Oncology, at the University of Chicago Pritzker School of Medicine, and Head of the University of Chicago Center for Radiation Therapy, and the director of the Chicago Tumor Institute. He is also Co- Director of the Ludwig Center for Metastasis Research at the University of Chicago.  

Dr. Weichselbaum's research interests include mechanisms of tumor spread and how radiation therapy and immunotherapy can be used to better treat cancer. He is also studying patterns of gene expression in human tumors that confer resistance to radiotherapy and chemotherapy. Weichselbaum invented a radio-inducible form of gene therapy TNFerade, which is currently in clinical trials. His research has been funded by the National Institutes of Health for more than 35 years.

He is also editor of Cancer Medicine, a definitive reference textbook compiled to help oncologists and internists apply scientific principles to clinical practice.

He obtained his medical degree from the University of Illinois at Chicago. Following a research fellowship in surgical oncology, he completed his residency at the Harvard Medical School's Joint Center for Radiation Therapy. He did a fellowship with John B. Little, M.D. at the Harvard School of Public HealthAfter completing this fellowship he joined the faculty of the Harvard Medical School, remaining a faculty member reaching the rank of Associate Professor in the Department of Radiation Oncology. He was jointly appointed in Cancer Biology at the Harvard School of Public Health. In 1984 he was recruited as Chair of the Department of Radiation & Cellular Oncology in the Division of Biological Sciences at the University of Chicago to head up their program and has remained there since.

Richard M. Stone, M.D.

Professor of Medicine, Harvard Medical School, Chief of Staff, Director Adult Leukemia, Dana Farber Cancer Institute

Dr. Stone received his M.D. from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at Dana Farber Cancer Institute. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.

His team’s research involves identifying novel targets involved in the pathophysiology of acute leukemia and myelodysplastic syndrome. Inhibition of the FLT3 tyrosine kinase, for example, may offer benefits in AML patients - especially those whose blasts have an activating mutation in the enzyme - similar to the success of imatinib in the treatment of patients with chronic myeloid leukemia (CML). After conducting several trials with FLT3 inhibitors as single agents in myeloid malignancies, they are now focusing on combining these drugs with chemotherapeutic agents. His laboratory continues to explore the mechanism of leukemic transformation via mutated FLT3, especially regarding activation of downstream pathways such as protein kinase A or AKT, which may be involved in key aspects of leukemogenesis such as prevention of apoptosis and promotion of self-renewal. Other areas of clinical research include targeted therapy in T cell ALL, based on inhibition of NOTCH activation, a common survival mechanism in such cells; application of intensive "pediatric-type" strategies in adults with ALL; and many novel drugs in AML in AML and MDS including histone deacetylase inhibitors, NEDD-8 inhibitors, HSP90 inhibitors, MEK inhibitors and others.

Advisors

Matthew L. Sherman M.D.

Former Executive Vice President and Chief Medical Officer Acceleron

Dr Sherman is the former Executive Vice President and Chief Medical Officer Acceleron and prior to this, Senior Vice President and Chief Medical Officer at SyntaPharmaceuticals.  He has held clinical development leadership positions and Wyeth Pharmaceuticals and Genetics Institute.

Dr. Sherman received his medical degree with honors from Dartmouth Medical School.  He is board certified in Medical Oncology and Internal Medicine.  He held clinical positions at Harvard Medical School and corresponding hospital appointments at Dana-Farber Cancer Institute and Brigham and Women’s Hospital.

Dr. Kufe has founded companies that include Genus Oncology, GenVec (acquired by Intrexon), Convergence Pharmaceuticals (acquired by ILEX Oncology and Genzyme), Linus Oncology (acquired by Gibson Oncology) and NanoProteagen (merged with Hillstream).  

Lynne Bui, M.D.

Experienced Oncology Clinical Drug Developer


David Weaver, M.D.

Vice President, Translational Medicine at Verastem

David Weaver has pioneered contributions to pharmaceutical and academia research, drug discovery, development and diagnostics of cancer and immune disorders for over 30 years. Prior to pharma, David Weaver was on Harvard University faculty of in Microbiology and Molecular Genetics, and Immunology, engaged in fundamental cancer and immunology research. He has served in senior scientific, founder, and development positions in several biotech/pharma and diagnostic companies. Dr. Weaver led Biology at Daiamed (Daichi-Sankyo, previously Suntory Pharmaceuticals) in immune and cardiovascular disease drug discovery. David was then the Chief Scientific Officer at DNAR (2005-2008), followed by On-Q-ity (2008-2011), developing personalized medicine companion diagnostics for cancer. From 2011, David has served at Verastem in various capacities, Head of Biomarkers, Vice President of Research, Vice President Translational Medicine. David led the Research and Development teams for therapies on Cancer Stem Cells, Immuno-Oncology and heme malignancies, and was a key contributor in the 2018 FDA approval of duvelisib (COPIKTRATM). Currently, David leads Life Cycle Management for the duvelisib Product Development portfolio.
Dr. Weaver is an author >125 journal articles, and an inventor on 35 patents or patent applications, served on editorial boards for different medical and scientific journals, been a long-term member of AACR, ASCO, ASH, EHA, biomedical professional organizations, and speaker at many conferences. Dr. Weaver has served as a Scientific Advisor and Advisory Board member for FemtoDx, Praxeon, Akanas Therapeutics, Nanoproteagen, OvaScience, Ninth Sense.

Harpal Singh, PhD

Professor of Biomedical Engineering, IIT-Delhi


Richard Lowenthal, MS, MSEL

Expertise in complex regulatory submissions and accelerated pathways


Hillstream is this Month’s Recipient of BioNJ's Emerging Company in the Spotlight